Skip to main
PSTV

PSTV Stock Forecast & Price Target

PSTV Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Plus Therapeutics is a clinical-stage pharmaceutical company with a positive outlook, due to its promising pipeline of potential products targeting CNS cancers and rare diseases. The recent reverse stock split is deemed to have a risk/reward positive effect, as the company maintains its BUY rating with lowered 12-month price target, indicating significant upside potential. The recent Q4 results showcase the company's revenue growth and its focus on clinical trials for its lead candidate, REYOBIQ, an innovative treatment for GBM and LM. Additionally, the recent ISPOR analysis supports the economic value proposition of Plus Therapeutics' CNSide platform, which can potentially reduce healthcare costs by about 40%. The company is also focused on commercializing and scaling up manufacturing for REYOBIQ, expanding reimbursement coverage, and driving test volume growth.

Bears say

Plus Therapeutics is facing potential headwinds with its recent downgrade to Hold and a newly announced reverse stock split, indicating possible struggles to meet listing compliance and pressures on trading liquidity. While the company received major grant wins in 2022 and 2024, it continues to face significant EPS losses and could face difficulties in enrolling patients in its LM trial, casting doubts on its ability to successfully commercialize its main drug candidate, REYOBIQ.

PSTV has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Plus Therapeutics Inc (PSTV) Forecast

Analysts have given PSTV a Strong Buy based on their latest research and market trends.

According to 4 analysts, PSTV has a Strong Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Plus Therapeutics Inc (PSTV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.